HCG 5000 IU

Compound profile

hCG: compound profile, literature landscape and handling notes

Where hCG came from

hCG entered science as an activity before it was a molecule. In the late 1920s Selmar Aschheim and Bernhard Zondek reported that urine from pregnant women, when introduced into immature female mice, produced characteristic changes in the ovaries within a few days. The readout was anatomical and it required dissecting the animals, but it was reproducible, and it became the first practical pregnancy test. A rabbit version followed. The important historical point for anyone handling this material is that the original assay was a bioassay: the substance was defined operationally, by what it did to a living tissue, years before anyone isolated it, sequenced its subunits or knew it was glycosylated. The analyte that the Aschheim-Zondek test detected is the same analyte that every strip pregnancy test on a pharmacy shelf still detects today, which is an unusual degree of continuity for a biochemical assay.

That history is the direct cause of the labeling convention on this vial. Because the substance was quantified by biological comparison from the beginning, an international standard was established as a physical reference preparation, and material is expressed in International Units defined against it. The unit is a statement about potency relative to that standard, not about how many molecules or milligrams are present. Successive WHO International Standards have been established as earlier stocks were exhausted, each calibrated against its predecessor.

Material has traditionally been recovered and purified from the urine of pregnant women, which is also why the classical preparations are described by their source rather than by a synthesis route. Recombinant forms produced in Chinese hamster ovary cells exist and are a genuinely different product, expressed from cloned subunit genes and carrying the glycosylation profile of the host cell line rather than of human trophoblast. Urinary-derived and recombinant preparations are both hCG in the sense that both are the same two gene products assembled into the same dimer, and they are not the same reagent.

Reading the structure of hCG

The specification table further down this page prints what the product record states for this listing. What is worth explaining here is the architecture, because it is not the architecture of anything else in this catalog and the differences are consequential.

hCG is a dimer of two different chains that are not joined by a covalent bond. They associate non-covalently, tightly, and the assembled dimer is the active species; the free subunits are essentially inactive at the receptor. This means the molecule has a failure mode that a single-chain peptide does not have, namely coming apart while both of its pieces remain perfectly intact and perfectly detectable.

The alpha subunit is the surprising part. It is identical to the alpha subunit of luteinizing hormone, follicle-stimulating hormone and thyroid-stimulating hormone. One gene, one product, shared across four hormones. All of the specificity therefore lives in the beta subunit, which is unique to each hormone and determines which receptor the assembled dimer reads. The hCG beta subunit is the closest relative of the LH beta subunit, sharing a large majority of its sequence, and the two hormones act at the same receptor for exactly that reason.

The feature that distinguishes hCG beta from LH beta is a C-terminal extension of roughly two dozen residues, universally abbreviated CTP, that LH beta does not have. The CTP carries a cluster of O-linked glycans. Its function is not receptor contact. It is a clearance modifier: the sialylated O-linked sugars on that tail slow renal elimination substantially, so hCG persists in circulation far longer than LH does despite acting at the same receptor. This is the single most engineered-looking feature of a natural protein in this catalog, and it was later exploited deliberately, which the literature section returns to.

Both subunits fold into a cystine-knot topology, the same fold family used by several growth factors, in which one disulfide bond threads through a macrocycle formed by two others. Multiple additional disulfides stabilize each chain. Both chains carry N-linked glycans in addition to the O-linked cluster on the CTP.

The consequence of all this glycosylation is that hCG is not a single molecular entity. It is a population of glycoforms sharing one polypeptide backbone and differing in branching, sialylation and site occupancy of their sugars. There is no one correct molecular weight for it, only a distribution, and the distribution depends on the source.

The target and the pathway in more detail

The receptor is LHCGR, the luteinizing hormone/choriogonadotropin receptor, a class A G-protein-coupled receptor with an unusually large extracellular domain built from leucine-rich repeats. That ectodomain is where the hormone actually binds; the leucine-rich-repeat horseshoe provides a broad concave surface that the dimer docks onto, and the signal is then propagated into the seven-transmembrane bundle through a hinge region. This is architecturally very different from the small-molecule-style binding pockets of most class A receptors, and it is why the ligand is a large glycoprotein rather than a short peptide. Coupling is primarily to Gs, raising intracellular cyclic AMP and activating protein kinase A, with additional Gq-mediated phospholipase C signaling reported at higher occupancy.

The point most worth making about LHCGR is where it sits. It is expressed on gonadal cells, at the bottom of the hypothalamic-pituitary-gonadal axis. hCG therefore acts directly on the effector tissue of that axis, downstream of everything else. This is a sharp contrast with several other listings in this catalog. Kisspeptin-10 acts on KISS1R on hypothalamic GnRH neurons, three levels up. GnRH and its analogs act on the pituitary gonadotroph, two levels up, and their effect on the gonad is entirely indirect and entirely dependent on an intact pituitary. Growth hormone secretagogues such as sermorelin operate on the analogous parallel branch at the pituitary. If an experiment is intended to interrogate axis integrity, the level at which a compound enters the axis is the whole experiment, and hCG enters at the last possible stop.

Because LH and hCG share a receptor, the two hormones are pharmacologically similar and kinetically quite different, and the difference is the CTP. A receptor that is presented with a short-lived ligand and a long-lived ligand experiences different occupancy profiles even at matched potency, and downstream desensitization and receptor internalization behave accordingly. The published record on LHCGR internalization and recycling is a real body of work in its own right.

There is one further cross-reactivity worth naming because it is genuine and documented rather than folkloric. The glycoprotein hormone receptors are structurally related, and the shared alpha subunit plus the close relationship of the beta subunits means hCG has weak agonist activity at the thyrotropin receptor. The affinity is low relative to TSH itself, but the phenomenon is real, has been characterized in receptor-expression systems, and is the accepted explanation for a well-described gestational endocrine observation.

What the published literature on hCG actually measures

The published literature that uses hCG divides into four fairly distinct territories, and a citation from one of them is frequently misapplied in another.

The first is reproductive endocrinology, which is the largest and oldest. Within it, hCG is used both as the subject of study, as the trophoblast product that maintains the corpus luteum in early pregnancy, and as a pharmacological tool that supplies LH-like receptor occupancy with a long duration of action. The tool-compound use is why the compound appears in so many protocols that are not about hCG at all.

The second is protein engineering, and it is the most interesting for a reader coming from the rest of this catalog. Once it was understood that the CTP was responsible for the clearance difference between hCG and LH, the obvious experiment was to graft that tail onto other proteins and see whether the effect transferred. It did. CTP fusion became an established half-life-extension strategy alongside PEGylation, albumin binding and Fc fusion, and it produced at least one licensed long-acting gonadotropin built by attaching the hCG beta CTP to a different beta subunit. When you read the acylation-and-albumin-binding logic in the incretin entries in this catalog, the CTP is the glycoprotein-world answer to the same problem, arrived at first by evolution and then borrowed.

The third is oncology, where hCG functions as a tumor marker. It is the definitive marker for gestational trophoblastic disease and is measured alongside alpha-fetoprotein in germ cell tumors. This literature is a marker literature, meaning it is about measuring the analyte accurately over an enormous concentration range, and it has driven much of the assay development.

The fourth is the clinical-chemistry and immunoassay literature, which is where a bench scientist should actually go for methodological detail. hCG is measured by two-site sandwich immunoassay, and the field has documented its failure modes in unusual depth: the hook effect, in which very high analyte concentration saturates both capture and detection antibodies independently and drives the signal back down, producing a falsely low reading from an extremely high sample; heterophilic antibody interference; and above all the problem of what the assay is actually detecting. Intact dimer, free beta subunit, nicked forms and the beta core fragment are all present in real samples in varying proportions, and different antibody pairs see different mixtures of them. Standardization efforts in this area are ongoing and the reference materials are explicitly defined by which species they represent.

Where the hCG literature is thin or frequently misread

The most common and most consequential error with this material is treating International Units as a mass proxy. IU are defined against a biological standard by potency comparison. A given mass of one preparation and the same mass of another do not carry the same number of units if their glycoform distributions differ, because sialylation and branching change circulating persistence and therefore the bioassay readout. Any IU-to-milligram figure quoted anywhere is a property of one preparation measured one way, not a physical constant, and it should never be carried across from a different product. This is the single point on this page most worth remembering.

The second is the assumption that urinary-derived and recombinant hCG are interchangeable. They share a polypeptide sequence and they differ in glycosylation, because trophoblast and Chinese hamster ovary cells do not build identical sugars. Glycoform differences propagate into clearance behavior, into immunoassay recognition and into how a preparation behaves in a bioassay. Comparative work exists but it is smaller than the volume of casual assertions that the two are equivalent.

The third is the popular-claim problem, which is unusually large for this compound. A weight-loss protocol built around hCG was promoted from the mid-twentieth century onward and became widely repeated. It was subsequently tested in controlled trials, and the controlled literature did not support the claims made for it. That is a factual statement about a body of published evidence and it is the only thing this page will say on the subject. The relevance here is analytical rather than anything else: a very large fraction of the non-scientific text written about this molecule descends from that episode, which means an ordinary literature search returns a poor signal-to-noise ratio and secondary sources about hCG need more skepticism than secondary sources about most catalog items.

The fourth is subtler. Because hCG is so easy to detect by immunoassay, it is easy to assume detection equals potency. The two are separate measurements, and the assumption fails in a specific direction described in the next section.

How hCG behaves in solution

hCG is a protein, so its solution failure modes are protein failure modes, not peptide failure modes. Nothing in this section is reconstitution arithmetic; that belongs to another block on this page.

The characteristic vulnerability is subunit dissociation. The dimer is held together non-covalently, so it can come apart under conditions that leave both chains chemically undamaged: low pH, chaotropes, elevated temperature, extreme dilution, and interfaces. Dissociated subunits do not activate the receptor. A preparation can therefore lose biological activity without losing any material, without any visible change and without any bond being broken, which is a mode of failure that a short synthetic peptide simply does not have.

Surface adsorption is a serious and underappreciated issue at low concentration. A glycoprotein at nanogram-per-milliliter levels in an untreated tube can lose a large proportion of its content to the walls, and unlike a small peptide it does not readily come back off. This is the situation where the addition of an inert carrier protein to the buffer is a genuine methodological necessity rather than a refinement, and it is standard practice in the assay literature for exactly this reason. It also changes the matrix, so it has to be recorded.

Freeze-thaw cycling is damaging for the usual reasons, amplified here: the ice-water interface promotes both surface denaturation and dissociation, and a dimer that has come apart during freezing does not necessarily reassemble on thawing. Aggregation is the other end of the same process, producing soluble oligomers and eventually visible particulates. A solution that has gone cloudy, developed a faint haze against a dark background, or left a film on the vial wall has already told you something.

The single most useful insight about this material is that potency and immunoreactivity are different measurements and they degrade at different rates. A dissociated or partially denatured preparation frequently retains most of its epitopes, so a sandwich immunoassay still reports the analyte as present at close to the expected concentration while the receptor-mediated activity has fallen substantially. Immunoassay content is not a potency assay. Treating it as one is how a degraded preparation passes unnoticed.

Analytical notes specific to hCG

This is where hCG departs furthest from the rest of the catalog, and the departure is worth stating bluntly. Reversed-phase HPLC area-percent purity, the workhorse number for every synthetic peptide on this site, is largely inappropriate for a heterogeneously glycosylated non-covalent dimer. The glycan population spreads the material across a retention window rather than a peak, the denaturing mobile phase pulls the dimer apart during the separation so that what elutes is not what was loaded, and an area percent computed from that chromatogram is not describing the entity of interest. A certificate offering a single figure such as ninety-nine percent by HPLC for this material is a category error rather than a reassurance, and recognizing that is more useful to a buyer than any number would be.

The methods that do apply are the protein-chemistry methods. SDS-PAGE run both reduced and non-reduced is the fastest orthogonal check available: non-reduced you look at what the dimer does, reduced you should resolve two bands corresponding to the two subunits, each running diffusely because glycosylated proteins do not migrate cleanly. Size-exclusion chromatography under non-denaturing conditions is the method of choice for the questions that actually matter, namely how much aggregate is present and how much of the material is assembled dimer versus free subunit. Ion-exchange or isoelectric focusing resolves the charge distribution created by sialic acid content, which is the closest thing available to a fingerprint of the glycoform population.

Immunoassay gives immunoreactive content, and it should be understood as answering the question of how much epitope is present, nothing more. Potency in International Units requires a potency measurement: a classical bioassay against the reference preparation, or a cell-based assay in an LHCGR-expressing line reading cyclic AMP accumulation, calibrated against the standard. Only that class of experiment produces a number in the unit printed on the label.

Intact mass by electrospray mass spectrometry does work, but it returns a glycoform envelope rather than a single deconvoluted mass, and interpreting it requires either releasing the glycans enzymatically first or accepting a distribution as the answer. Peptide mapping after deglycosylation confirms the polypeptide sequence of both chains and is the definitive identity method, at the cost of destroying the thing that makes the molecule interesting.

Compounds researchers confuse with hCG

Questions specific to hCG